Adamas Releases Final Results of Two-Year Phase 3 Trial of GOCOVRI® for Dyskinesia

(February 11, 2020) The longest-running amantadine study to date of the only FDA-approved medicine for dyskinesia indicates GOCOVRI may help people with PD who are struggling to manage levodopa-related motor complications. Read more.